Search Results
Jun 29, 2026, 10:31 ET Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight
nephrotic syndrome therapies in clinical trials include Inaxaplin (VX-147), Apecotrep (BI 764198), GAZYVA/GAZYVARO (obinutuzumab), Zetomipzomib (KZR-616), Atacicept, WAL0921, and others.Discover the nephrotic syndrome drug pipeline analysis report @
More news about: DelveInsight Business Research, LLP
Apr 14, 2026, 16:13 ET Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-kzr-eqh-ulyx-obtaining-fair-deals-for-their-shareholders-302742200.htmlSOURCE
More news about: Halper Sadeh LLP
Apr 10, 2026, 13:34 ET Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-apls-cnta-kzr-obtaining-fair-deals-for-their-shareholders-302739362.htmlSOURCE
More news about: Halper Sadeh LLP
Apr 08, 2026, 14:15 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS
KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955
More news about: Monteverde & Associates PC
Apr 07, 2026, 14:47 ET Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-kzr-talk-wbd-obtaining-fair-deals-for-their-shareholders-302736030.htmlSOURCE
More news about: Halper Sadeh LLP
Mar 31, 2026, 11:17 ET Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-kzr-nsa-eqh-ctra-obtaining-fair-deals-for-their-shareholders-302730227.htmlSOURCE
More news about: Halper Sadeh LLP
Mar 30, 2026, 13:35 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
KZR) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive
More news about: Monteverde & Associates PC
Mar 30, 2026, 12:25 ET Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia.
More news about: Ademi LLP